O

    Oncolytics Biotech Inc (ONCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.84
    -0.02 (-2.15%)

    Market Cap: $106.88M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -14.80%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.07
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.07+2.6%
    60d ago$-0.08+0.7%
    30d ago$-0.08+0.7%
    7d ago$-0.08+0.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.08---
    Jun 26
    Reported Aug 6
    		$-0.08$-0.07-14.29%Miss-14.3%
    Mar 26
    Reported May 14
    		$-0.11$-0.07-57.14%Miss-37.5%
    Dec 25
    Reported Mar 30
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    Reported Nov 12
    		$-0.14$-0.07-100.00%Miss-16.7%
    Jun 25
    Reported Aug 8
    		$-0.07$-0.08+12.50%Beat+30.0%
    Mar 25
    Reported May 14
    		$-0.08$-0.09+11.11%Beat+11.1%
    Dec 24
    Reported Mar 7
    		$-0.10$-0.13+23.08%Beat-100.0%
    Sep 24
    Reported Nov 12
    		$-0.12$-0.11-9.09%Miss+7.7%
    Jun 24
    Reported Aug 1
    		$-0.10$-0.11+9.09%Beat+9.1%
    Mar 24
    Reported May 9
    		$-0.09$-0.11+18.18%Beat+10.0%
    Dec 23
    Reported Mar 7
    		$-0.05N/A+66.67%Beat+66.7%
    Sep 23
    Reported Nov 3
    		$-0.13$-0.11-18.18%Miss-62.5%
    Jun 23
    Reported Aug 14
    		$-0.11$-0.11+0.00%Beat-22.2%
    Mar 23
    Reported May 5
    		$-0.10$-0.14+28.57%Beat+16.7%
    Dec 22
    Reported Mar 3
    		$-0.15$-0.10-50.00%Miss-7.1%
    Sep 22
    Reported Nov 7
    		$-0.08$-0.11+27.27%Beat+11.1%
    Jun 22
    Reported Aug 11
    		$-0.09$-0.10+10.00%Beat+30.8%
    Mar 22
    Reported May 5
    		$-0.12$-0.14+14.29%Beat+7.7%
    Dec 21
    Reported Mar 3
    		$-0.14$-0.13-7.69%Miss+36.4%
    Sep 21
    Reported Nov 5
    		$-0.09$-0.12+25.00%Beat+43.8%
    Jun 21
    Reported Aug 6
    		$-0.13$-0.12-8.33%Miss+18.8%
    Mar 21
    Reported May 7
    		$-0.13$-0.15+13.33%Beat-208.3%
    Dec 20
    Reported Mar 5
    		$-0.22$-0.15-46.67%Miss+15.4%
    Sep 20
    Reported Nov 11
    		$-0.16$-0.13-23.08%Miss+0.0%
    Jun 20
    Reported Aug 4
    		$-0.16$-0.14-14.29%Miss+38.5%
    Mar 20
    Reported May 8
    		$0.12$-0.19+163.16%Beat+144.4%
    Dec 19
    Reported Mar 5
    		$-0.26$-0.14-85.71%Miss+7.1%
    Sep 19
    Reported Nov 12
    		$-0.16$-0.20+20.00%Beat+20.0%
    Jun 19
    Reported Aug 13
    		$-0.26$-0.25-4.00%Miss+3.7%
    Mar 19
    Reported May 2
    		$-0.27$-0.29+6.90%Beat+3.6%
    Dec 18
    Reported Mar 8
    		$-0.28$-0.24-16.67%Miss+26.3%
    Sep 18
    Reported Nov 12
    		$-0.20$-0.28+28.57%Beat-5.3%
    Jun 18
    Reported Aug 3
    		$-0.27$0.05-640.00%Miss+3.6%
    Mar 18
    Reported May 11
    		$-0.28$-0.19-47.37%Miss+0.0%
    Dec 17
    Reported Mar 9
    		$-0.38$-0.28-35.71%Miss+19.1%
    Sep 17
    Reported Nov 8
    		$-0.19$-0.38+50.00%Beat+32.1%
    Jun 17
    Reported Aug 3
    		$-0.28$-0.28+0.00%Beat-
    Mar 17
    Reported May 5
    		$-0.28$-0.38+26.32%Beat-
    Dec 16
    Reported Mar 10
    		$-0.47$-0.28-67.86%Miss-
    Sep 16
    Reported Nov 3
    		$-0.28$-0.28+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.32EV/EBITDA-1.79x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-769.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.35xQuick Ratio1.35x
    Trading Statistics
    Beta1.14Avg Volume633.80K
    52-Week High$1.5152-Week Low$0.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.84
    SMA 20$0.83
    SMA 50$0.85
    SMA 200$0.94
    EMA 10$0.84
    EMA 20$0.83
    EMA 50$0.85
    EMA 200$0.91

    MACD

    Line: 0.00Signal: -0.00Hist: 0.01

    ADX

    ADX: 8.6+DI: 18.1-DI: 16.1

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$0.82

    Bollinger Bands

    Upper Band$0.87
    Lower Band$0.78
    %B Position1050%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    50.7

    Momentum Oscillators

    Stoch %K76.8
    Stoch %D82.8
    Williams %R-36.6
    ROC (10d)1.9%
    Momentum0.02
    CCI (20d)77.0
    MFI (14d)55.6

    Volatility Measures

    ATR (14d)$0.04(5.0%)
    StdDev (20d)0.02
    Hist Vol38.6%(Moderate)

    Volume Flow

    VWAP$0.85
    OBV24.9M
    AD Line-27.9M
    CMF (20d)0.207

    Volume Metrics

    Avg Vol (20d)628.1K
    Vol Ratio0.7x
    VWMA (20d)$0.83

    Pivot Points

    R3$0.91
    R2$0.89
    R1$0.87
    Pivot Point$0.85
    S1$0.83
    S2$0.81
    S3$0.79

    Advanced Oscillators

    TSI3.33
    Ultimate Osc62.9
    KST12.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$79,000$0$0N/A$72,000$71,623$123,000$107,000$76,793
    Gross Profit$0$0N/A$-79,000$0$0N/A$-72,000$-71,623$-123,000$-107,000$-76,793
    Operating Expenses$9.38M$9.28M$2.99M$13.84M$4.65M$5.02M$8.44M$9.90M$5.72M$8.60M$8.74M$8.16M
    R&D$4.26M$4.55M$2.96M$7.51M$1.92M$2.80M$4.55M$6.79M$3.33M$5.74M$4.66M$4.33M
    SG&A$5.12M$4.73M$6.89M$6.23M$2.73M$2.22M$3.46M$3.10M$3.26M$2.86M$4.08M$5.24M
    Operating Income$-9,379,000$-9,281,000N/A$-13,840,000$-4,651,000$-5,021,000$-8,437,000$-9,899,000$-5,788,337$-8,726,000$-8,849,000$-8,237,030
    Interest Income$37,000$44,000$0$100,000$-288,000$117,000$152,000$261,000$340,000$446,000$489,000$305,000
    Interest Expense$0$0$0$812,000$565,000$0$0$0$0$0$0$0
    Income Before Tax$-9,341,000$-9,243,000$-1,730,255$-14,652,000$-5,216,000$-4,711,000$-7,994,000$-9,531,000$-5,233,622$-6,894,000$-3,906,000$-7,394,539
    Income Tax Expense$101,000$0$337,543$-252,000$61,000$0$23,000$12,000$69,430$79,724$43,000$5,218
    Net Income$-9,442,000$-9,243,000$-2,067,799$-14,400,000$-5,277,000$-4,711,000$-8,017,000$-9,543,000$-5,303,052$-6,894,000$-3,949,000$-7,399,758
    EBITDA$-9,363,000$-9,271,000N/A$-14,559,000$-4,910,000$-4,809,000$-8,339,000$-9,794,000$-5,161,995$-8,603,000$-8,742,000$-7,317,741
    EBIT$-9,378,000$-9,287,000N/A$-14,652,000$-4,928,000$-4,828,000$-8,437,000$-9,899,000$-5,233,618$-8,726,000$-8,849,000$-7,394,534
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ONCY

    News

    ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

    Oncolytics Biotech (ONCY) has received positive feedback from the FDA regarding the registrational pathway for its drug pelareorep in treating RAS-mutant, MSS metastatic colorectal cancer (CRC), allowing for a potential pivotal expansion of the REO 033 trial. The FDA's support for using objective response rate (ORR) for accelerated approval and progression-free survival (PFS) for full approval indicates an efficient path forward. Additionally, pelareorep has been granted Fast Track designation for second-line and later anal cancer, further validating the drug's potential and Oncolytics' technology.

    Yahoo Finance•8/27/26•
    Bullish

    ONCY Should I Buy

    Oncolytics Biotech Inc. (ONCY) is analyzed as a potential buy due to recent positive developments, including a new patent and FDA Fast Track designation for Pelareorep, with a current stock price of $0.84 significantly below analyst targets of $5. However, concerns exist regarding its financial sustainability, marked by a high forward P/E of 45.4545 and consistent net income losses, including a substantial loss in Q2 2026. Analysts from H.C. Wainwright and Lake Street maintain "Buy" ratings despite lowering their price targets.

    Intellectia AI•8/22/26•
    Somewhat-Bullish

    HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings

    HC Wainwright has revised its FY2026 earnings per share forecast for Oncolytics Biotech (NASDAQ:ONCY) to a loss of $0.30, down from $0.28, while maintaining a "Buy" rating and a $5.00 price target. The biotechnology company recently reported a quarterly loss of $0.08 per share, missing consensus estimates, and analysts anticipate continued losses in the coming years. Despite weak stock performance and multiple negative sentiment revisions to earnings forecasts, Oncolytics Biotech has gained FDA alignment on its REO 033 trial, providing some positive news.

    MarketBeat•8/21/26•
    Somewhat-Bearish

    Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright

    HC Wainwright has reduced its price target for Oncolytics Biotech (NASDAQ:ONCY) to $5.00, while maintaining a "Buy" rating, implying a significant potential upside. The company reported a quarterly loss of $0.08 per share, missing estimates. Analyst sentiment is mixed, with a consensus "Moderate Buy" rating, and institutional investors own 6.82% of the company.

    MarketBeat•8/19/26•
    Somewhat-Bearish

    H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift

    H.C. Wainwright has lowered its price target for Oncolytics Biotech (NASDAQ:ONCY) shares to $5 from $10, while maintaining a Buy rating. This adjustment follows the company's decision to de-prioritize its squamous cell carcinoma of the anal canal program in favor of a strategic partnership. Despite this, Oncolytics Biotech is making progress with its REO 033 trial for metastatic colorectal cancer, with an initial tumor response update expected by year-end 2026, and has also received Fast Track designation for its anal cancer therapy, pelareorep.

    Investing.com•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About ONCY

    Does ONCY pay dividends?
    Oncolytics Biotech Inc (ONCY) does not currently pay a regular dividend.
    What is ONCY's market cap?
    Oncolytics Biotech Inc (ONCY) has a market capitalization of $106.88M with a current stock price of $0.84.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In